Drugs / IBI319
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04708210 | Apr 2021 → Dec 2022 | cancer | Innovent Biologics (Suzhou) Co. Ltd. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-11-08 | Innovent Biologics (Suzhou) Co. Ltd. | Results Innovent Publishes the Preclinical Results of IBI319 (Anti PD-1/CD137 Bispecific Antibody) in Nature Communications innoventbio.com ↗
The pre-clinical results show that IBI319 enhances the antitumor efficacy of PD-1 blockade without causing hepatotoxicity: |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-11-08 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent Publishes the Preclinical Results of IBI319 (Anti PD-1/CD137 Bispecific Antibody) in Nature Communications innoventbio.com ↗ |
| 2021-07-16 | Innovent Biologics (Suzhou) Co. Ltd. | Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI319 (Anti-PD-1/CD137 Bispecific Antibody) in Patients with Advanced Malignant Tumors innoventbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI319 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04708210 ↗ |
| Route | Intravenous | “Iv infusion day 1 of every 14 or 21 days” NCT04708210 ↗ |